News

Published on 31 May 2024 on Zacks via Yahoo Finance

FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD

Article preview image

Sanofi SNY and Regeneron REGN announced that the FDA extended the review period for a regulatory filing seeking label expansion for their blockbuster drug Dupixent in chronic obstructive pulmonary disease (COPD) indication by an additional three months. A final decision is now expected by Sep 27, 2024.

The FDA filing seeks approval for Dupixent as an add-on maintenance treatment in certain adult patients with uncontrolled COPD.

Read the rest of the article
NASDAQ.REGN price evolution
NASDAQ.SNY price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease

On Friday, the FDA extended the target action date of priority review of supplemental application...

Benzinga 31 May 2024
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD

Sanofi SNY and Regeneron REGN announced that the FDA extended the review period for a regulatory ...

Zacks via Yahoo Finance 31 May 2024
Recent Circuit Litigation Continues to Highlight “But-For” Causation Requirement for the Government...

The spotlight is now on U.S. v. Regeneron Pharmaceuticals, Inc., which is currently being briefed...

The National Law Review 28 May 2024
Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution

The fact that multiple Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders offloaded a conside...

Simply Wall St. via Yahoo Finance 27 May 2024
The Biggest Biotechnology Company in Europe

We've recently covered a list of 20 Biggest Publicly-Traded Biotech Companies based on market cap...

Insider Monkey via Yahoo Finance 27 May 2024
Cencora data breach exposes US patient info from 8 drug companies

Cencora, formerly AmerisourceBergen, is a pharmaceutical services provider specializing in drug...

BleepingComputer 24 May 2024
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information...

U.S. drug wholesaler Cencora Inc (NYSE:COR), formerly AmerisourceBergen, is notifying affected...

Benzinga via AOL 24 May 2024
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?

Key Insights Regeneron Pharmaceuticals' estimated fair value is US$1,903 based on 2 Stage Free Ca...

Simply Wall St. via Yahoo Finance 22 May 2024
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript May 2, 2024 Regene...

Insider Monkey via Yahoo Finance 3 May 2024
3 Glenmede Mutual Funds for Maximizing Returns

The Glenmede Trust Company (GTC) founded in 1956, provides a range of investment strategies, incl...

Zacks via Yahoo Finance 3 May 2024

Copyright Statfolio @ 2024

Social Accounts